yahoo_financeOriginal article
Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis
NDA FilingfenebrutinibPositive
AI Analysis
Summary
Roche's fenebrutinib has received U.S. FDA filing acceptance as the first BTK inhibitor in both relapsing and primary progressive multiple sclerosis indications.
Outcome Details
FDA filing acceptance for BTK inhibitor in relapsing and primary progressive multiple sclerosis
Importance:7/10
Sentiment:
0.70
BTK inhibitormultiple sclerosisFDA filingfirst-in-class
Related Companies
Read the original article
Published by yahoo_finance on September 30, 2026 5:00 AM